利用TCGA和GEPIA2公共数据库分析ACSM3与卵巢癌预后的关系

Analysis on relationship between ACSM3 and ovarian cancerprognosis by TCGA and GEPIA2 public databases

目的 研究肿瘤基因图谱(TCGA)数据库中酰基辅酶A合成酶中链家族成员3(ACSM3)在357例卵巢癌患者中的表达量及其与患者生存状况的关系。方法 对TCGA数据库中357例卵巢癌患者的ACSM3表达量及其与生存情况的关系进行分析,寻找其共表达基因并进行基因本体(GO)富集分析和京都基因与基因组百科全书(KEGG)富集分析。结果 多因素Cox回归分析进一步表明,ACSM3是卵巢癌患者预后的影响因素,其共表达基因富集分析结果与炎症应答和肿瘤中基因异常转录相关。结论 ACSM3的表达对卵巢癌患者的预后具有重要的意义,高表达预后较好。ACSM3可以成为指导临床医师评估卵巢癌患者预后的重要指标。

Objective To investigate relationship between the expression levels of Acyl-CoA medium-chain synthetase 3(ACSM3)and the survival status of 357 patients with ovarian cancer in the cancer genome atlas(TCGA)database.Methods The expression levels of ACSM3 and their relationship with survival conditions in 357 patients with ovarian cancer in TCGA database were analyzed,and co-expression genes of ACSM3 were searched for gene ontology(GO)enrichment analysis and Kyoto encyclopedia of genes and genomes(KEGG)enrichment analysis.Results Multivariate Cox regression analysis further indicated that ACSM3 was a prognostic factor for patients with ovarian cancer,and its co-expression gene enrichment analysis results were associated with inflammatory response and abnormal gene transcription in tumors.Conclusion The expression of ACSM3 is of great significance for the prognosis of patients with ovarian cancer,and high expression of it has better prognosis.ACSM3 can be an important indicator for guiding clinicians to evaluate the prognosis of patients with ovarian cancer.